UNSPSC 51141570: Riluzole

This classification denotes an anticonvulsant agent with the molecular formula C8H5F3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LJ087RS6F, chemically known as 2-benzothiazolamine, 6-(trifluoromethoxy)- but generally known as riluzole, which bears US NIH Compound Identifier 5070. European Medicines Agency schedules Riluzole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10319MIG.

UNSPSC 51141570 Riluzole, a Commodity code, nominally encompasses pharmaceutical procurement for the neurological treatment riluzole. However, the recent state and local activity tagged under this code shows a mismatch: the single opportunity on file solicits naloxone and drug deactivation systems for harm reduction and emergency response, not riluzole formulations. The code does not reflect established demand for riluzole itself in recent state and local solicitations, suggesting either sparse activity under the intended pharmaceutical scope or a cataloging inconsistency in how state and local procurement offices have tagged related pharmaceutical purchases.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford. The IFB requires electronic bid submission, E-Verify compliance, drug-free workplace certification, and specific insurance coverage; the contract carries a two-year initial term with a one-year renewal option and a three-month probationary termination clause. Given the single recent opportunity and its divergence from the code's nominal scope, firms pursuing pharmaceutical contracts in state and local markets should verify how individual jurisdictions classify riluzole and related pharmaceutical lines before relying on this code for opportunity tracking.